TESARO, Inc. today announced that the U.S. FDA has approved Varubi™ (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

READ FULL ARTICLE Curated publisher From ir.tesarobio.com